Fig. 2: Current RMP market.

Meta-analysis of the current RMP space lends visibility into the level of activity in the field as well as its recent trends. A The eras of biologics and RNA. Illustrative data shows the rapid market capitalization growth rate RMPs contrasted with the comparatively slower market capitalization growth rate of biologics. B Market capitalization by technology. The total market capitalization of companies with RNA technology assets (excluding diversified companies, such as Merck, Pfizer, and Sanofi) from 2018 to 2022 is broken down by RNA technology and is compared to the S&P 500. Numbers above each bar represent the number of companies included in the analysis and the total market capitalization for that year. The market capitalization for publicly traded companies was estimated by multiplying historical closing share prices on December 31^st for each year by the outstanding shares. This data was obtained from Yahoo Finance, accessed May 17, 2023. The data for the S&P 500 was obtained from Yahoo Finance and accessed May 17, 2023. Standard statistical methods were used in the analysis of the data. *Some 43 private companies working with mRNA raised ~ $1.6B in funding from 2021 to 2022. C Number of programs by RNA class in 2023. The total volume of preclinical and active clinical programs in January of 2023 is represented in descending order. Data was obtained from Beacon Intelligence, RNA dataset, accessed April 1st, 2023. Data View used in the RNA dataset was ‘Drug Data.’ D 2023 mRNA pipeline by therapeutic area. The number of mRNA programs in 2023; all phases of development are broken down by therapeutic area. Data was obtained from Beacon Intelligence, RNA dataset, accessed April 1st, 2023. Data View used in the RNA dataset was ‘Drug Data.’ ASO antisense oligonucleotide, Cap capitalization, CircRNA circular RNA, CV cardiovascular, gRNA guide RNA, Ph phase, siRNA small interfering RNA.